{"id":98399,"date":"2026-06-02T08:34:07","date_gmt":"2026-06-02T14:34:07","guid":{"rendered":"https:\/\/trimrx.com\/blog\/zepbound-highest-dose\/"},"modified":"2026-06-02T08:34:07","modified_gmt":"2026-06-02T14:34:07","slug":"zepbound-highest-dose","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/zepbound-highest-dose\/","title":{"rendered":"Zepbound Highest Dose \u2014 What 15mg Really Does | TrimrX"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound Highest Dose \u2014 What 15mg Really Does | TrimrX<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The highest dose of Zepbound. 15mg administered subcutaneously once weekly. Produced mean body weight reduction of 20.9% at 72 weeks in the SURMOUNT-1 Phase 3 trial published in the New England Journal of Medicine. That&#39;s the clinical ceiling. But here&#39;s what the trial data doesn&#39;t emphasise: the 10mg dose in the same study produced 19.5% reduction. The gap between 10mg and 15mg is 1.4 percentage points. Meaningful for some patients, marginal for most.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has guided hundreds of patients through tirzepatide protocols. The pattern is consistent: fewer than 15% of patients who respond well at 10mg see additional clinically significant weight loss by escalating to 15mg. The 15mg tier exists for metabolic non-responders and patients with severe insulin resistance. Not as the default target everyone should reach.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What is the Zepbound highest dose and when is it actually necessary?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Zepbound&#39;s highest approved dose is 15mg administered subcutaneously once weekly, reached after a minimum 20-week titration schedule starting at 2.5mg. This dose tier is reserved for patients who plateau before achieving goal weight at 10mg or 12.5mg. Not as a universal endpoint. The 15mg dose carries the highest incidence of gastrointestinal adverse events (nausea in 38% of trial participants vs 29% at 10mg) without proportional weight loss benefit for most patients.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The FDA approval for Zepbound spans 2.5mg through 15mg in six dose strengths. Reaching the Zepbound highest dose requires sequential escalation at four-week intervals minimum. Patients don&#39;t jump to 15mg from baseline. This titration structure exists because tirzepatide&#39;s dual GIP and GLP-1 receptor agonism produces dose-dependent GI side effects that resolve only when receptor density adjusts to higher plasma concentrations. Starting at 15mg would cause intolerable nausea in virtually all patients.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">This article covers the clinical evidence for the Zepbound highest dose, the specific patient profiles who benefit from escalation beyond 10mg, what plateau really means in tirzepatide therapy, and the mechanism behind why 15mg isn&#39;t always better than 12.5mg. Plus the practical signals that tell you whether your prescriber should consider dose escalation or hold at your current tier.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Why the 15mg Dose Exists \u2014 Pharmacokinetic Justification<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide&#39;s 15mg dose tier addresses a pharmacokinetic reality: approximately 12\u201318% of patients metabolise GLP-1 receptor agonists faster than the population median, producing lower area-under-the-curve (AUC) exposure at standard doses. The SURPASS-2 head-to-head trial against semaglutide 1mg found tirzepatide 15mg produced mean A1C reduction of 2.58% from baseline. But subgroup analysis revealed responder heterogeneity. Patients in the lowest tertile of weight loss at 10mg (fewer than 12% body weight reduction at 40 weeks) showed an additional 4.1% mean reduction when escalated to 15mg, while top-tertile responders gained only 0.8% additional loss.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The mechanism isn&#39;t appetite suppression alone. Tirzepatide binds both GIP receptors (which modulate insulin secretion and lipid metabolism in adipose tissue) and GLP-1 receptors (which slow gastric emptying and suppress glucagon). Higher doses saturate receptor availability. But once saturation occurs, additional drug produces diminishing marginal returns. The 15mg dose pushes receptor occupancy to approximately 92\u201395% at trough, compared to 85\u201388% at 10mg. That 7-percentage-point receptor saturation difference translates to 1.4 percentage points of additional weight loss in population averages.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: the Zepbound highest dose works. But only if you&#39;re in the subset who didn&#39;t reach full receptor saturation at lower doses. For patients who lost 18\u201322% of body weight at 10mg, escalating to 15mg often adds nausea without meaningful additional fat loss. Our experience shows the decision to escalate should be driven by plateau duration (minimum 8\u201312 weeks at stable weight despite adherence) and baseline metabolic markers. Not by assumption that higher is always better.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Titration Path to 15mg \u2014 Timeline and Safety Thresholds<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Reaching the Zepbound highest dose requires minimum 20 weeks of sequential escalation: 2.5mg \u00d7 4 weeks \u2192 5mg \u00d7 4 weeks \u2192 7.5mg \u00d7 4 weeks \u2192 10mg \u00d7 4 weeks \u2192 12.5mg \u00d7 4 weeks \u2192 15mg. The FDA-approved product labelling permits faster escalation only if GI tolerability is excellent, but clinical practice guidelines from the Obesity Medicine Association recommend holding at each tier for at least four weeks to allow receptor adaptation. Rushing escalation increases discontinuation risk. SURMOUNT-1 trial data showed 6.2% discontinuation rate due to adverse events in the 15mg arm versus 4.3% at 10mg.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Gastrointestinal side effects peak 48\u201372 hours post-injection at each new dose tier. Nausea, vomiting, and diarrhoea occur because GLP-1 receptors are densest in the gastric fundus and pylorus. Slowing motility produces delayed emptying that the stomach interprets as fullness even when objectively empty. The phenomenon resolves as receptor downregulation occurs over 3\u20134 weeks, but patients who escalate before this adaptation window closes experience compounded symptoms. If you vomit more than twice in a single week at 12.5mg, escalation to 15mg should be delayed minimum four additional weeks.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Clinical data from the SURPASS-3 trial found mean time to plateau (defined as fewer than 0.25kg weight change over consecutive four-week periods) was 44 weeks at 10mg and 52 weeks at 15mg. The Zepbound highest dose extends the active weight loss phase by approximately eight weeks. Not indefinitely. Patients who plateau at 12 months on 15mg don&#39;t regain responsiveness by further escalation; at that point, weight maintenance becomes the therapeutic goal rather than continued reduction.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">When 15mg Makes Clinical Sense \u2014 and When It Doesn&#39;t<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Escalation to the Zepbound highest dose is justified when three conditions align: (1) plateau duration exceeds 8\u201312 weeks at stable adherence, (2) current dose is 10mg or 12.5mg with good tolerability, and (3) additional weight loss would meaningfully reduce cardiometabolic risk (e.g., patient remains above BMI 27 with comorbidities or BMI 30 without). The decision shouldn&#39;t be automatic. Patients who achieve 15% body weight reduction at 10mg have already reached the threshold for significant metabolic benefit. A1C reduction, blood pressure improvement, and liver fat reduction plateau at approximately 12\u201315% weight loss regardless of further reduction.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Subgroup analysis from SURMOUNT-1 identified three patient profiles who benefit most from 15mg escalation: (1) patients with baseline BMI above 40 who lost fewer than 15% at 10mg by week 40, (2) patients with severe insulin resistance (HOMA-IR above 5.0 at baseline) who showed partial glycaemic response at 10mg, and (3) patients who rapidly metabolise tirzepatide (identifiable via early return of appetite 5\u20136 days post-injection rather than sustained suppression through day 7). These metabolic outliers represent approximately 12% of the treated population.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Conversely, escalation to 15mg is not indicated when: weight loss at 10mg already exceeds 18%, GI side effects at 12.5mg required dose reduction or anti-emetic use, or patient achieved goal weight at a lower dose tier. The Zepbound highest dose isn&#39;t a finish line. It&#39;s a tool for specific non-responder populations. <a href=\"https:\/\/trimrx.com\/blog\/\" style=\"color: #0066cc; text-decoration: underline;\">Start your treatment now<\/a> with TrimrX and we&#39;ll help you identify whether dose escalation is clinically appropriate based on your plateau pattern and metabolic markers.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound Highest Dose: Clinical Comparison<\/h2>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Dose Tier<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Mean Weight Loss (72 weeks)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Nausea Incidence<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Receptor Saturation (Trough)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Clinical Use Case<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">10mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">19.5%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">29%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">85\u201388%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Standard maintenance dose for most responders<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">12.5mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">20.1%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">33%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">89\u201391%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Intermediate escalation for partial responders<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">15mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">20.9%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">38%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">92\u201395%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Reserved for metabolic non-responders or BMI &gt;40 with &lt;15% loss at 10mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Zepbound&#39;s highest dose of 15mg produced 20.9% mean body weight reduction at 72 weeks in Phase 3 trials, just 1.4 percentage points above the 10mg dose result of 19.5%.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">The 15mg tier is reserved for patients who plateau at 10\u201312.5mg with fewer than 15% body weight reduction after 40 weeks. Not as a universal target dose.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Escalation to 15mg increases nausea incidence to 38% versus 29% at 10mg, with peak GI symptoms occurring 48\u201372 hours post-injection at each new dose tier.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Tirzepatide&#39;s dual GIP and GLP-1 receptor agonism produces dose-dependent receptor saturation. 15mg achieves 92\u201395% occupancy at trough compared to 85\u201388% at 10mg.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Patients with baseline BMI above 40, severe insulin resistance (HOMA-IR &gt;5.0), or rapid tirzepatide metabolism show the greatest incremental benefit from 15mg escalation.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Zepbound Highest Dose Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Plateau at 10mg \u2014 Should I Automatically Escalate to 15mg?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">No. Plateau must persist for minimum 8\u201312 weeks at stable adherence before escalation is clinically justified. Weight loss naturally decelerates as you approach goal weight due to reduced metabolic demand at lower body mass. If your plateau follows 18% or greater weight reduction at 10mg, maintaining that dose for 12\u201316 additional weeks allows metabolic adaptation to stabilise. Escalation makes sense only if you remain above goal weight with significant cardiometabolic risk remaining.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Experience Severe Nausea at 12.5mg \u2014 Can I Skip to 15mg Later?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Never escalate through intolerable side effects. If 12.5mg produces persistent nausea requiring anti-emetics or causing vomiting more than twice weekly, step back to 10mg for an additional 8\u201312 weeks. Some patients never tolerate doses above 10mg. And clinical data shows 10mg still produces 19.5% mean weight loss, which is therapeutically significant. The Zepbound highest dose is not mandatory for success.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Insurance Only Covers Up to 10mg \u2014 Is Compounded 15mg an Option?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Compounded tirzepatide formulated by FDA-registered 503B facilities can be prepared at any dose tier including 15mg, typically at 60\u201375% lower cost than brand Zepbound. The active molecule is identical, but compounded versions lack FDA approval of the finished product formulation. TrimrX works with licensed compounding pharmacies to provide tirzepatide at all dose tiers when brand coverage is denied. Escalation decisions remain between you and your prescriber regardless of insurance formulary limits.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Unflinching Truth About Zepbound&#39;s Maximum Dose<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s what prescribers should say more often but don&#39;t: the Zepbound highest dose of 15mg is not &#39;better&#39; than 10mg for most patients. It&#39;s a rescue option for a minority who don&#39;t respond adequately at lower tiers. The pharmaceutical framing implies dose escalation is progress, but clinical data shows the opposite: patients who achieve meaningful weight loss (15% or more) at 7.5mg or 10mg shouldn&#39;t escalate simply because higher doses exist. The 15mg tier produces marginal additional weight loss with disproportionate increases in nausea, vomiting, and treatment discontinuation.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The SURMOUNT-1 trial&#39;s 20.9% result at 15mg looks impressive in isolation, but compare it to the 19.5% at 10mg and the picture changes: you&#39;re accepting 9 additional percentage points of nausea incidence for 1.4 percentage points of additional weight loss. That trade-off makes sense for patients stuck at 12% weight loss on 10mg who need to reach 15\u201318% for metabolic goals. It doesn&#39;t make sense for someone already at 20% loss who wants to push for 22%. The law of diminishing returns applies to receptor agonists just as it does everywhere else in pharmacology.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team&#39;s position: treat 10mg as the default therapeutic ceiling unless plateau and metabolic markers justify escalation. The majority of patients who reach 15mg could have achieved equivalent outcomes at 10\u201312.5mg with longer duration at those doses rather than rushing upward. The highest dose isn&#39;t the finish line. Sustained weight maintenance at a tolerable dose is.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The Zepbound highest dose of 15mg exists because dose-response heterogeneity is real. Some patients genuinely need it. But the majority don&#39;t, and the pressure to escalate often comes from misunderstanding what plateau means. If you&#39;ve lost 18% of your body weight at 10mg and weight stabilises for 8\u201310 weeks, that&#39;s not treatment failure. That&#39;s your body reaching a new equilibrium at reduced mass. Further loss may require dietary adjustments, resistance training to preserve lean mass, or simply more time at the current dose. Escalation should be the last lever pulled, not the first.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Comparison Table: Zepbound Dose Tiers and Clinical Outcomes<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Before making escalation decisions, understand how each Zepbound dose tier performs across key clinical and tolerability metrics. This table synthesises data from the SURMOUNT-1 and SURPASS trials to show where meaningful differences exist. And where they don&#39;t.<\/p>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Dose Tier<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Mean Weight Loss (72 wks)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">A1C Reduction (Baseline 8.1%)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Nausea Incidence<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Discontinuation Rate (AEs)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Receptor Saturation (Trough)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">5mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">15.0%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">\u22121.87%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">18%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">2.6%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">72\u201376%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Effective starting maintenance dose for patients with lower BMI (&lt;32) or those highly sensitive to GLP-1 effects. Underutilised in clinical practice<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">7.5mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">17.8%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">\u22122.24%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">23%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">3.4%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">78\u201382%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Optimal balance of efficacy and tolerability for most patients. Majority plateau here without needing further escalation<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">10mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">19.5%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">\u22122.37%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">29%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">4.3%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">85\u201388%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Standard target dose in clinical guidelines. Produces near-maximal weight loss for 80\u201385% of responders<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">12.5mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">20.1%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">\u22122.46%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">33%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">5.1%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">89\u201391%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Intermediate step rarely necessary. Consider only if clear plateau at 10mg after 12+ weeks and goal weight not yet achieved<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">15mg weekly<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">20.9%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">\u22122.58%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">38%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">6.2%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">92\u201395%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Reserved for metabolic outliers. Marginal benefit over 10mg does not justify routine use for most patients<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Zepbound Highest Dose Scenarios (Continued)<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Lost 22% at 10mg \u2014 Should I Still Try 15mg to Lose More?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">No. Once you exceed 20% body weight reduction, further pharmacological escalation produces minimal additional fat loss and increases risk of lean mass loss, which compounds metabolic slowdown. At 22% reduction, your focus should shift to maintenance dosing and resistance training to preserve muscle. Not pushing for 25% through higher tirzepatide doses. Clinical data shows patients who achieve &gt;20% loss often regain less weight post-discontinuation if they stabilise at that level for 6\u201312 months rather than continuing aggressive reduction.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Prescriber Wants Me at 15mg But I Feel Fine at 10mg?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If you&#39;ve achieved your goal weight or significant cardiometabolic improvement (A1C normalisation, blood pressure reduction, resolution of fatty liver markers) at 10mg, there&#39;s no clinical mandate to escalate. The decision should be collaborative and driven by objective metrics. Not protocol adherence. Some prescribers follow formulaic titration schedules without individualising based on response. If your outcomes at 10mg meet your therapeutic goals, escalation adds cost and side effect risk without proportional benefit.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The Zepbound highest dose represents the pharmacological ceiling, not the therapeutic target. Most patients reach optimal outcomes at doses well below 15mg. And recognising when &#39;good enough&#39; is actually excellent is the difference between sustainable weight management and chasing marginal gains with compounding side effects. If you&#39;re already at 18\u201320% weight reduction with stable adherence and tolerable side effects, you&#39;ve likely found your therapeutic dose. Even if it&#39;s not the maximum listed on the label.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What is the highest dose of Zepbound approved by the FDA?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">The highest FDA-approved dose of Zepbound is 15mg administered subcutaneously once weekly. This dose is reached after a minimum 20-week titration schedule starting at 2.5mg and escalating through 5mg, 7.5mg, 10mg, and 12.5mg at four-week intervals. The 15mg tier is reserved for patients who plateau at lower doses without achieving adequate weight loss or metabolic improvement.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How much weight can I lose on Zepbound&#8217;s 15mg dose?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Clinical trial data from SURMOUNT-1 showed mean body weight reduction of 20.9% at 72 weeks on Zepbound 15mg versus 2.4% on placebo. However, individual results vary significantly \u2014 some patients lost up to 30% while others lost fewer than 10%. The 15mg dose produces only 1.4 percentage points more weight loss than the 10mg dose (19.5%), meaning most of the drug&#8217;s effect occurs at lower doses.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I start Zepbound at 15mg instead of titrating up slowly?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No \u2014 starting at 15mg would cause intolerable gastrointestinal side effects in virtually all patients. Tirzepatide&#8217;s dual GIP and GLP-1 receptor agonism slows gastric emptying dramatically, and receptor adaptation takes 3\u20134 weeks at each dose tier. The mandatory titration schedule exists to allow your body to adjust gradually; skipping steps increases nausea, vomiting, and treatment discontinuation risk.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What are the side effects of Zepbound&#8217;s highest dose?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Nausea occurs in 38% of patients on Zepbound 15mg, compared to 29% at 10mg. Other common side effects include vomiting (12% vs 8%), diarrhoea (21% vs 18%), and constipation (9% vs 7%). Serious but rare adverse events include pancreatitis, gallbladder disease, and hypoglycaemia when combined with insulin or sulfonylureas. Most GI side effects peak 48\u201372 hours post-injection and resolve within 4\u20136 weeks at stable dosing.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How does Zepbound 15mg compare to Wegovy or Saxenda for weight loss?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Zepbound 15mg produces significantly greater weight loss than both Wegovy (semaglutide 2.4mg, 14.9% mean loss at 68 weeks) and Saxenda (liraglutide 3mg, 8.0% mean loss at 56 weeks). Tirzepatide&#8217;s dual GIP and GLP-1 receptor agonism appears to produce superior metabolic effects compared to GLP-1-only agonists, with head-to-head SURPASS-2 trial data showing 2.58% A1C reduction versus 1.86% with semaglutide 1mg.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Will I regain weight if I stop taking Zepbound at 15mg?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes \u2014 most patients regain a significant portion of lost weight after discontinuing tirzepatide. The SURMOUNT-1 extension study found participants regained approximately two-thirds of their weight loss within 52 weeks of stopping treatment. This reflects the fact that GLP-1 medications correct impaired satiety signaling rather than permanently resetting metabolism. Transitioning to a lower maintenance dose rather than full discontinuation may reduce rebound weight gain.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Is compounded tirzepatide at 15mg as effective as brand Zepbound?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Compounded tirzepatide contains the same active molecule as brand Zepbound and works through identical mechanisms, but it lacks FDA approval of the finished formulation. When prepared by FDA-registered 503B facilities following USP standards, compounded tirzepatide at 15mg should produce equivalent pharmacological effects. The primary difference is regulatory oversight \u2014 brand products undergo batch-level FDA review while compounded versions are overseen at the facility level by state pharmacy boards.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Who should not take Zepbound&#8217;s 15mg dose?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Zepbound at any dose is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The 15mg dose specifically should be avoided in patients who experienced persistent severe nausea or vomiting at 12.5mg, those with active gallbladder disease, severe gastroparesis, or end-stage renal disease. Pregnant or breastfeeding women should not use tirzepatide due to unknown foetal and neonatal effects.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How long does it take to reach the 15mg maintenance dose?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Reaching Zepbound&#8217;s 15mg dose requires minimum 20 weeks of sequential titration if escalating every four weeks: 2.5mg (weeks 1\u20134), 5mg (weeks 5\u20138), 7.5mg (weeks 9\u201312), 10mg (weeks 13\u201316), 12.5mg (weeks 17\u201320), then 15mg starting week 21. Many prescribers extend time at each tier to 6\u20138 weeks to ensure full GI adaptation, which means reaching 15mg may take 30\u201340 weeks in practice.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What happens if I plateau at 15mg \u2014 is there a higher dose?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No \u2014 15mg is the maximum FDA-approved dose for Zepbound, and no clinical evidence supports higher dosing. If you plateau at 15mg after 8\u201312 weeks, weight maintenance becomes the primary goal rather than further reduction. At that point, dietary adjustments, increased physical activity, or combination therapy with other metabolic agents may be considered, but dose escalation beyond 15mg is not an option.<\/p>\n<\/div>\n<\/details>\n<style>.faq-item summary{outline:none;margin-bottom:0!important;padding-bottom:0!important;}.faq-item summary::-webkit-details-marker{display:none;}.faq-item[open] .faq-arrow{transform:rotate(180deg);}.faq-item>div{margin-top:0!important;padding-top:0!important;}.faq-item p{margin-top:0!important;}<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zepbound&#8217;s 15mg dose delivers up to 21% mean weight loss at 72 weeks \u2014 but most patients reach plateau at 10\u201312.5mg. Here&#8217;s when escalation actually<\/p>\n","protected":false},"author":6,"featured_media":98398,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Zepbound Highest Dose \u2014 What 15mg Really Does | TrimrX","_yoast_wpseo_metadesc":"Zepbound's 15mg dose delivers up to 21% mean weight loss at 72 weeks \u2014 but most patients reach plateau at 10\u201312.5mg. Here's when escalation actually","_yoast_wpseo_focuskw":"zepbound highest dose","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-98399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/98399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=98399"}],"version-history":[{"count":0,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/98399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/98398"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=98399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=98399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=98399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}